about
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytesCost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange programThe pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenzA single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratioInfectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.Pharmacotherapy in the treatment of addiction: methadone.Improving the quality of substance dependency treatment with pharmacotherapy.Therapeutic drug monitoring in methadone maintenance: choosing a matrix.Efavirenz therapy in drug users.Pharmacokinetics of methadone.Tuberculosis and illicit drug use: review and update.Methadone maintenance and tuberculosis treatment.Methadone: antimicrobial activity and interaction with antibiotics.Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.Clinical use of methadone.Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsDrug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.Clinical care of the HIV-infected drug userPXR antagonists and implication in drug metabolism.ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.Interindividual variability of methadone response: impact of genetic polymorphism.The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism.Nervous system effects of antituberculosis therapy.Methadone: a review of drug-drug and pathophysiological interactions.Pharmacogenomics of methadone maintenance treatment.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.Pruritus possibly associated with a portosystemic shunt in a bichon frise puppyMetabolism and pharmacokinetics of the antibiotic rifampin.Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases.The integration of medical management with recovery.Methadone-disulfiram interaction during methadone maintenance.Induction of propranolol metabolism by rifampicin.HIV-infected intravenous drug users in methadone maintenance treatment: clinical problems and their management.The use of levo-alpha-acetylmethadol (LAAM) in methadone patients who have not achieved heroin abstinence.Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.
P2860
Q24564971-59270792-817B-4B39-9F9B-79A23E6B1C40Q24649164-9879F866-D8DE-4566-B445-8097455E0234Q28359547-9D8636C6-9F6A-4B03-AD7E-FEA31CEBEDBDQ28362277-3D03F12D-0B25-4626-8963-61268236F232Q28363552-8CD42030-6676-473C-AE89-E5A1A42817D6Q30395708-2CCE0F27-F3B9-4200-BA5A-9175958075F7Q30724632-623544EC-9128-4157-90AF-F7F707124674Q33914167-3190701F-4546-4C9C-B15C-995174383935Q34118712-3BF9E7E8-C68C-4EB0-B9E7-E42A4937A2ACQ34229211-1654BE68-5C10-4CA5-9EF4-C525817FF4FFQ34459338-9B528548-E1D9-46FA-90A5-3C0B33AB5DE2Q34487284-899840A8-587F-4487-8876-B60E974B22EEQ34601143-170C11D7-2EF4-45DE-9E91-2F47565B6E67Q34735732-AE0D1F3F-00BA-4AB1-9E66-1229B46CBCF6Q34989293-536949F5-8DE7-4402-9D8E-3A65DF101281Q35594405-B4924506-7A55-413C-89FA-229C454BD3BFQ35598093-6C2C8BE8-1B9E-402D-902F-FBAD3804BF63Q35738851-6B943836-B3D4-4DA9-9D67-B8B56B031B79Q35738885-8C69044C-D5C6-43AF-A494-F8DC146071A6Q35906594-1C67242A-0676-469B-A66E-C06CE1EA2281Q36054984-E44F0411-809B-4517-B25E-9E5879C90AC4Q36248580-97F450FC-436B-41B4-8F8F-A2C63C644BFAQ36640752-7120C7BF-2CB0-47C3-9D99-52D716332CBBQ37008505-D497E5E6-C210-4F62-B3A8-54CCBFA7F211Q37142009-237B2C15-43FA-47C6-9DB6-F06541D52B52Q37523782-E900BAA4-D0D7-4CD8-9F6D-57CA5507E539Q37775611-7197B582-A637-48F7-8220-FD5F922B3D0DQ37950478-1B52FE5D-B558-4D83-B3B7-F43F50CE251CQ38222510-B561CC27-4757-479A-8F4B-659E89407A19Q38478413-3C24CA12-A6C1-4411-9945-3E332FC13C46Q38880647-9DD31F5D-45DD-4614-A68A-2319F36A6810Q40317983-BD307181-83D3-49D1-9675-EC2A496102B5Q41247930-13007DAD-7590-4CE3-8F1B-ECCA45AA0774Q41618800-D4E047BB-9A9F-486D-8DEC-BBD5CB7C1378Q41646891-2397BE32-10D8-497C-8A38-36619FAF9E38Q43262011-099379E5-8263-4EFB-A8EF-C96BFA7CC86FQ43903843-D96B4CF6-96EF-49AD-AA3E-08C8742D77C8Q44048390-1AF0ADB9-A781-4A5E-AEA8-27902D97BA0FQ44500239-E779053C-3F97-4334-9615-9E502DEF53E9Q51694212-48E1C6E0-48BC-4FAF-A7E8-8218BB04B956
P2860
description
1976 nî lūn-bûn
@nan
1976 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
Rifampin-induced methadone withdrawal
@ast
Rifampin-induced methadone withdrawal
@en
Rifampin-induced methadone withdrawal
@nl
type
label
Rifampin-induced methadone withdrawal
@ast
Rifampin-induced methadone withdrawal
@en
Rifampin-induced methadone withdrawal
@nl
prefLabel
Rifampin-induced methadone withdrawal
@ast
Rifampin-induced methadone withdrawal
@en
Rifampin-induced methadone withdrawal
@nl
P2093
P1476
Rifampin-induced methadone withdrawal
@en
P2093
C L Gutjahr
J W Garfield
L M Giusti
P304
P356
10.1056/NEJM197605132942008
P407
P577
1976-05-13T00:00:00Z